PharmaTimes |
Merck discontinues HCV programmes
PharmaTimes Merck & Co has announced that it will discontinue the development of the investigational combination regimens MK-3682B (grazoprevir/ruzasvir/ uprifosbuvir) and MK-3682C (ruzasvir/uprifosbuvir) for the treatment of chronic hepatitis C virus (HCV) infection. |
from Health - Google News http://ift.tt/2x1ZvKd
EmoticonEmoticon